Hematopoietic stem cell

Lore & Background

They are round, non-adherent cells with a rounded nucleus and low cytoplasm-to-nucleus ratio, resembling lymphocytes. During embryonic development in mice and humans, the first definitive HSCs appear in the aorta-gonad-mesonephros region and the vitelline and umbilical arteries, later also in the placenta, yolk sac, embryonic head, and fetal liver. In adults, they reside in the red bone marrow, where haematopoiesis occurs. HSCs are multipotent and capable of extensive self-renewal. They give rise to myeloid and lymphoid lineages, including monocytes, macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes (to platelets), T cells, B cells, natural killer cells, and innate lymphoid cells. Subtypes include colony-forming units such as CFU-GEMM, CFU-L, CFU-E, CFU-GM, CFU-Meg, CFU-Baso, and CFU-Eos. The colony-forming unit–spleen (CFU-S) was used in early studies but is now considered to measure more mature progenitor cells. HSCs mostly exist in a state of quiescence, regulated by the MEK/ERK and PI3K/AKT/mTOR pathways. They have a higher potential than other immature blood cells to pass the bone marrow barrier and travel in the blood, enabling harvest directly from peripheral blood after cytokine stimulation. HSC transplantation is used for cancers such as multiple myeloma and leukemia, as well as immune disorders, autoimmune diseases, and hereditary skeletal dysplasias. While HSCs are best characterized in vertebrates, some invertebrates (e.g., planarians, arthropods) possess cells with hematopoietic stem cell-like properties, overturning the earlier notion that these cells are exclusive to vertebrates.

Reader's Guide

Hematopoietic stem cells are foundational to modern medicine due to their role in haematopoiesis and regenerative therapy. Their ability to self-renew and differentiate into all blood cell types makes them critical for treating life-threatening blood cancers and immune disorders through transplantation. The discovery that HSC niches exist in invertebrate skeletons overturned the long-held belief that skeletal hematopoiesis is unique to vertebrates. HSCs are isolated using flow cytometry based on cell surface markers like CD34 and lack of lineage markers. Their quiescent state in the hypoxic bone marrow environment allows long-term survival, but dysregulation can lead to stem cell exhaustion. Transplantation remains dangerous, with complications including infection and graft-versus-host disease, yet it is established therapy for chronic myeloid leukemia, acute lymphatic leukemia, aplastic anemia, hemoglobinopathies, acute myeloid leukemia, and primary immune deficiencies. Ongoing research aims to expand HSC populations in vitro for therapeutic use.

Did You Know?

• The first definitive HSCs arise from the ventral endothelial wall of the embryonic aorta in the aorta-gonad-mesonephros region.
• HSCs can be harvested from peripheral blood after donors are injected with granulocyte-colony stimulating factor (G-CSF).
• While HSCs are best known in vertebrates, some invertebrates (e.g., planarians, arthropods) have cells with hematopoietic stem cell-like properties, challenging the idea that these cells are exclusive to vertebrates.

Clinical Frontline – Treating Blood Cancers

Hematopoietic stem cell transplantation stands as the most established and widely practiced form of stem-cell therapy, with a clinical history stretching back more than nine decades. Its primary battlefield is blood cancers—leukemia and lymphoma—where conventional chemotherapy presents a brutal paradox. Cytotoxic agents, designed to destroy rapidly dividing malignant cells, cannot distinguish between a leukemia cell and the healthy hematopoietic stem cells residing in the bone marrow. The result is that the very cells needed to rebuild the patient's blood system are wiped out alongside the tumor. HSCT addresses this by introducing a donor's healthy bone marrow or peripheral blood stem cells, effectively reseeding the patient's marrow with functional precursors. Beyond simple replacement, the transplanted cells mount an immune response that actively hunts residual cancer cells. However, this same immune aggression can turn against the patient's own tissues, producing graft-versus-host disease—the procedure's most dangerous complication.

The Regulatory Map – What Is Actually Approved

As of 2024, the regulatory landscape for stem-cell medicine remains strikingly narrow. Hematopoietic stem cell transplantation is the sole FDA-approved stem-cell therapy in the United States, typically delivered through bone marrow, peripheral blood, or umbilical cord blood sources. The FDA has specifically cleared five distinct hematopoietic stem-cell products derived from cord blood for treating blood and immunological disorders. Beyond the U.S., the European Medicines Agency recommended approval of limbal stem cells in 2014 for patients suffering severe eye damage from burns. In Canada, a different class of stem-cell therapy—Prochymal, based on mesenchymal stem cells purified from adult donor bone marrow—received conditional approval in 2012 to manage acute graft-versus-host disease in children who had not responded to steroid treatment. A single adult donor's marrow can yield up to ten thousand frozen doses, stored until a child's condition demands them. Despite these milestones, the approved catalog remains modest compared to the breadth of conditions researchers hope to address.

Ethical Crossroads and Public Controversy

Stem-cell research has never been free from public and political friction. The ability to isolate and culture embryonic stem cells, to perform somatic cell nuclear transfer, and to generate induced pluripotent stem cells has ignited debates that spill well beyond the laboratory. Opposition to embryonic stem-cell work is frequently rooted in philosophical, moral, or religious objections, particularly because deriving new cell lines often requires destroying a blastocyst. These discussions are routinely entangled with abortion politics and the specter of human cloning. A separate controversy surrounds commercial efforts to market treatments built on stored umbilical cord blood, raising questions about efficacy and ethical marketing. The Geron Corporation's GRNOPC1 trial, which used embryonic stem-cell-derived oligodendrocyte progenitor cells for acute spinal cord injury, was cleared by the FDA in 2009 but ultimately discontinued in 2011 due to financial pressures. Its assets were later acquired by BioTime in 2013 with hopes of restarting the work, underscoring how economic realities can derail even ethically contentious but scientifically promising research.

Beyond the Marrow – Research Horizons

The research pipeline extending beyond hematopoietic stem cell transplantation is vast and still largely experimental. Scientists are investigating whether the molecules and exosomes released by stem cells—collectively termed the stem cell secretome—could be harnessed to develop standalone medications, particularly for degenerative, autoimmune, and inflammatory conditions. Paracrine soluble factors appear to be a key mechanism through which stem-cell therapies exert their effects, suggesting the therapeutic value may lie as much in signaling molecules as in the cells themselves. New harvesting sources are under active study: mesenchymal stem cells from skin and dermis offer minimal-risk collection, while hematopoietic stem cells circulating in the bloodstream have shown differentiating ability comparable to other mesenchymal types. Extra-embryonic sources—including the umbilical cord, yolk sac, and placenta—promise even greater differentiating potential, including the capacity to form tissues of endodermal and ectodermal origin. Researchers are also exploring applications in neurodegenerative diseases, diabetes, and heart disease, though none of these have yet crossed into approved clinical practice.